Apixaban versus Aspirin for Embolic Stroke of Undetermined Source.

Tobias Geisler, Timea Keller, Peter Martus,Khouloud Poli,Lina Maria Serna-Higuita,Juergen Schreieck,Meinrad Gawaz,Johannes Tünnerhoff,Paula Bombach, Thomas Nägele,Uwe Klose,Parwez Aidery,Patrick Groga-Bada,Andrea Kraft,Frank Hoffmann, Carsten Hobohm, Katrin Naupold,Ludwig Niehaus,Marc Wolf,Hansjörg Bäzner,Jan Liman,Rolf Wachter,Hubert Kimmig, Werner Jung,Roman Huber, Regina Feurer,Alfred Lindner,Katharina Althaus,Felix J Bode,Gabor C Petzold,Thanh N Nguyen,Brian Mac Grory,Matthew Schrag,Jan C Purrucker,Christine S Zuern,Ulf Ziemann,Sven Poli

NEJM evidence（2023）

引用 0|浏览8

暂无评分

摘要

Apixaban versus Aspirin for Embolic StrokeIn a trial of 352 patients with embolic stroke of undetermined source, 5 mg of apixaban administered twice daily was compared with 100 mg of aspirin administered once daily for the prevention of recurrent ischemic strokes. At 12 months, 13.6% of patients given apixaban had new ischemic lesions on magnetic resonance imaging compared with 16.0% of patients given aspirin, and the rates of clinically relevant bleeding were also comparable.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要